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activation within the kidney and of the 
challenge ahead to obtain evidence-based 
recommendations for the safe and effi  ca-
cious implementation of renoprotective 
interventions with VDR agonists. 
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 Programmed anti-inflammatory 
macrophages protect against 
AKI and promote repair 
through trophic actions 
 Christof    Westenfelder 1  
 Because pharmacological interventions for the treatment of acute 
kidney injury (AKI) have remained ineffective, cell-based therapies have 
been developed. Marrow stromal cells have been found to be safe and 
potentially effective in study subjects. Jung  et al. demonstrate that 
macrophages made to overexpress anti-inflammatory interleukin-10 
protect rats with AKI through iron-mediated upregulation of lipocalin-2 
and its receptors, eliciting both anti-inflammatory and proliferative 
responses. These data further advance our understanding of cell-based 
therapies for AKI. 
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 For interventions to be effective in the 
prevention and treatment of ischemia / 
reperfusion- and nephrotoxin-induced 
acute kidney injury (AKI), they must 
simultaneously and sequentially target all 
involved pathomechanisms and repair 
mechanisms. Th is requires that anti-infl am-
matory and broad trophic actions be elicited 
in parallel. Anti-infl ammatory actions must 
reduce the complex cellular and molecular 
infl ammatory responses seen in the injured 
kidney and, optimally, those in remote 
organs. Unless this is accomplished, both 
the protection and the repair of the injured 
kidney through targeting of the micro-
vasculature, inhibition of apoptotic and 
necrotic loss of tubular and endothelial cells, 
and stimulation of repair through angio-
genic and mitogenic signals are diminished 
or absent. In other words, neither trophic 
actions of a given intervention nor anti-
infl ammatory actions  per se are generally 
suffi  cient to adequately protect renal func-
tion and to repair the damaged organ. Th is 
paradigm is illustrated in  Figure 1a . 
 Clinical trials with bioactive factors such 
as atrial natriuretic peptide, 1 insulin-like 
growth factor-I, 2 and erythropoietin 3 have 
been essentially ineff ective in patients with 
AKI, while being convincingly benefi cial 
in preclinical studies in otherwise healthy 
animals. Several factors in the clinical 
design of these trials may have contributed 
to these disappointing outcomes. Unlike 
experimental animals, study subjects suf-
fered from various comorbidities; treat-
ment was started at diff erent time points 
following the oft en-delayed diagnosis of 
AKI; and the tested factors are not able to 
adequately elicit both anti-infl ammatory 
and trophic responses. Because of the con-
tinued lack of eff ective drug-based thera-
pies for AKI, novel therapies more recently 
began to test cell-based approaches. Th e 
rationale for this approach lies in the fact 
that adult stem and progenitor cells, such 
as multipotent marrow stromal cells, also 
termed mesenchymal stem cells (MSC), 
endothelial progenitor cells, and, under 
certain circumstances, hematopoietic stem 
cells, have been shown to be renoprotec-
tive in experimental AKI — responses 
mediated by the ability of these cells to 
home to the injured kidney, to effect a 
robust anti-infl ammatory response com-
bined with antiapoptotic, angiogenic, and 
mitogenic actions. These promising 
preclinical data generated with MSC 
treatment protocols formed the basis, in 
our hands, for a phase 1 clinical trial 4 
(NCT00733876). On-pump cardiac sur-
gery patients (coronary artery bypass sur-
gery and / or valve surgery) received 
allogeneic MSCs in a dose escalation pro-
tocol. Th ey were at increased risk for post-
operative AKI due to underlying chronic 
kidney disease, diabetes mellitus, and, at 
age 65 or above, hypertension, congestive 
heart failure, and chronic obstructive 
pulmonary disease. Th e intervention was 
found to be safe, length of hospital stay 
and readmission rates were reduced, and 
at time of discharge none of the study sub-
jects met the Acute Kidney Injury Network 
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or RIFLE criteria for AKI, a pattern that 
was distinct from that seen in well-
matched historical controls, of whom close 
to 20 % developed AKI postoperatively. 
And surprisingly, as was shown in our pre-
clinical studies, MSC therapy for AKI or 
its prevention in study subjects did also 
protect kidney function late aft er surgery, 
whereas historical controls with even mild 
postoperative AKI showed deterioration 
in renal function over time. 
 The role of bone marrow-derived 
monocytes / macrophages as central medi-
ators of both the infl ammatory response in 
and the subsequent repair of the acutely 
injured kidney is increasingly recognized. 5 
In elegant studies, Cantley ’ s group demon-
strated recently that adoptive transfer of 
interferon-  -activated proinfl ammatory 
M1 macrophages, positive for inducible 
nitric oxide synthase, worsened murine 
ischemia / reperfusion injury early in AKI, 
whereas anti-infl ammatory, wound-healing 
M2 macrophages, positive for mannose 
receptor and arginase, stimulated repair 
and improved outcomes. 6 When M1-
primed macrophages were depleted, reno-
protection was aff orded, whereas depletion 
of M2-primed macrophages worsened 
subsequent repair. It was also observed 
that during the course of experimental 
AKI there was a spontaneous switch from 
M1 to M2 phenotype, obviously represent-
ing a benefi cial adaptive response. 
 Several years ago, Kluth and colleagues 7 
transduced bone marrow-derived macro-
phages (BMDMs) with interleukin-10 
(IL-10), a potent anti-infl ammatory cyto-
kine. Infusion of these IL-10-overexpressing 
macrophages to animals with experimental 
glomerulonephritis proved surprisingly 
eff ective in ameliorating this infl ammatory 
disease. Th is genetic modifi cation of mac-
rophages transformed them into an anti-
inflammatory phenotype without their 
having to go through the M1-primed stage, 
as illustrated in  Figure 1b . 
 Th is ability of M1-type macrophages to 
assume the M2 phenotype, when appropri-
ately stimulated, was recently demonstrated 
by an important study by the groups 
of Mezey and Star. 8 These investigators 
demonstrated that administration of 
bone marrow-derived MSCs effectively 
attenuated peritonitis-induced sepsis in 
mice through their ability to reprogram 
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 Figure 1  |  Cell-based therapies of acute kidney injury (AKI): modes of action. ( a ) Effective cell-
based interventions in AKI (cells indicated by red arrows) simultaneously blunt the inflammatory 
response through robust anti-inflammatory, immune-modulating, and antioxidant activities at 
sites of injury (endothelial, tubular, and inflammatory cells). These activities provide essential 
 ‘ cover ’ for the cells ’ trophic actions that inhibit apoptosis, stimulate proliferation and angiogenesis, 
and prevent secondary development of interstitial fibrosis and chronic kidney disease. ( b ) Bone 
marrow-derived monocytes / macrophages (BMDMs) are primed by inflammatory stimuli to assume 
the M1 proinflammatory phenotype, which contributes to early worsening of AKI. A spontaneous, 
in AKI, or induced switch to the M2 wound-healing phenotype contributes to renal repair after AKI. 
Adenoviral transduction of BMDMs with interleukin-10 (IL-10), a major anti-inflammatory cytokine, 
renders them similarly renoprotective as M2 cells, mediated by upregulation of lipocalin-2 and its 
two receptors, responses that are iron-mediated. This  ex vivo programming of BMDMs skips the 
step of M1 priming and readily generates an organ-protective cell type. 
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host macrophages to increase their IL-10 
production, a prostaglandin E 2 -mediated 
response. We observed previously that 
MSC treatment of rats with AKI induced 
by ischemia / reperfusion injury was highly 
renoprotective, mediated by the upregula-
tion of renal IL-10 combined with the inhi-
bition of the intrarenal expression of tumor 
necrosis factor-  , IL-1  , and interferon-  . 9  
 Th ese robust anti-infl ammatory responses 
elicited by MSCs were accompanied by 
simultaneously expressed angiogenic, 
antiapoptotic, and mitogenic actions in the 
animals ’ kidneys. And signifi cantly, these 
complex eff ects were exclusively mediated 
by paracrine mechanisms. 
 Jung  et al. 10 (this issue) applied the ear-
lier observations of Kluth and colleagues, 7 
made in experimental glo me rulonephritis, 
to the treatment of experi mental AKI. Spe-
cifi cally, they tested whether the adminis-
tration of IL-10-overexpessing BMDMs 
was renoprotective in rats with AKI 
induced by ischemia / reperfusion injury. 
Th e rationale for this approach is again 
based on the recognition that AKI is char-
acterized by involvement of both innate 
and adaptive immunity, and that ameliora-
tion of inflammatory manifestations 
is needed in order for organ protection 
and repair stimuli to be eff ective. Com pared 
with non-IL-10-transduced BMDMs, 
the post-refl ow infusion of IL-10 BMDMs 
improved renal function, histo pathology, 
and local inflammation and led to the 
intrarenal upregulation of lipocalin-2 
(Lcn-2, or NGAL), its two receptors (Lcn-
2-R and megalin), stathmin, Ki-67, and 
proliferating cell nuclear antigen. Trans-
duction of BMDMs with an adenoviral 
vector for IL-10 resulted in an increase in 
their intracellular iron pool, which, in turn, 
caused upregulation of Lcn-2 and its two 
receptors. Th e anti-infl ammatory and pro-
liferative eff ects of IL-10 macrophages  in 
vitro and  in vivo were abolished by neutral-
izing anti-Lcn-2 antibodies and by defer-
oxamine, an iron chelator, respectively. 
Together, these observations demonstrate 
that the previously reported kidney-pro-
tective actions of Lcn-2 in AKI are medi-
ated by iron-induced upregulation of 
Lcn-2 and its receptors. Heme oxygenase-
1 (HO-1) is known to mediate the anti-
infl ammatory actions of IL-10, an enzyme 
that accelerates heme protein breakdown 
with augmented release of iron, carbon 
monoxide, and biliverdin. 11 However, the 
authors did not investigate the downstream 
involvement of HO-1 in their study. 
 Together, these detailed and well-designed 
studies are important observations, as 
they identify hitherto unknown signaling 
mechanisms whereby IL-10, delivered 
by reprogrammed macrophages, acts to 
reduce infl ammation and stimulate regene-
ration aft er AKI. Signifi cantly, these new 
data further confirm the paradigm that 
effective prevention and treatment of 
AKI depend on the combined expression of 
anti-infl ammatory as well as regenerative 
actions, the former being critical to the 
effi  cacy of the latter. Cell-based therapies 
with MSCs and IL-10-overexpressing 
BMDMs, unlike pharmacological interven-
tions, fulfi ll these criteria. 
 To date, cell-based approaches show sig-
nifi cant promise in the renal fi eld but must 
await additional, well-designed, adequately 
powered, randomized and controlled clini-
cal trials. Of note are the similarities in 
the modes of action of MSCs and IL-10-
expressing BMDMs. MSCs express IL-10 
and can induce IL-10 expression in host 
macrophages and other cells, thereby gen-
erating IL-10-expressing macrophages, a 
therapeutically eff ective phenotype that was 
created  a priori by Jung  et al. 10 It will have 
to be seen which cell type is the easiest to 
use and the most eff ective in the prevention 
and treatment of clinical AKI. 
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